2 weeks Ago By ABMN Staff
Townsquare Capital LLC trimmed its holdings in shares of Hologic, Inc. ( NASDAQ:HOLX – Free Report ) by 81.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
The firm owned 6,470 shares of the medical equipment provider’s stock after selling 27,851 shares during the period. Townsquare Capital LLC’s holdings in Hologic were worth $466,000 as of its most recent filing with the Securities and Exchange Commission. Several other large investors have also recently added to or reduced their stakes in the stock.
Barclays PLC raised its stake in shares of Hologic by 47.6% during the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock valued at $58,507,000 after purchasing an additional 231,578 shares during the period.
Wilmington Savings Fund Society FSB purchased a new stake in Hologic during the 3rd quarter worth $93,000. Tidal Investments LLC lifted its holdings in Hologic by 60.1% in the 3rd quarter.
Tidal Investments LLC now owns 15,351 shares of the medical equipment provider’s stock worth $1,250,000 after buying an additional 5,764 shares in the last quarter. Franklin Resources Inc. boosted its position in Hologic by 171.
7% in the 3rd quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider’s stock valued at $22,714,000 after buying an additional 175,855 shares during the last quarter.
Finally, Oddo BHF Asset Management Sas purchased a new position in Hologic in the 3rd quarter valued at about $1,110,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.
Hologic Stock Up 1.9 % NASDAQ:HOLX opened at $57.56 on Monday.
The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.
52. The stock has a 50 day moving average of $61.58 and a 200-day moving average of $70.
70. The firm has a market capitalization of $12.92 billion, a PE ratio of 18.
16, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82.
Hologic, Inc. has a 52 week low of $55.89 and a 52 week high of $84.
67. Analyst Ratings Changes HOLX has been the topic of several recent analyst reports. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th.
Raymond James reaffirmed an “outperform” rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th.
Stephens reissued an “overweight” rating and set a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Evercore ISI cut their price target on shares of Hologic from $76.
00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. Finally, Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $80.
00 to $75.00 in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company.
According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $84.62.
Check Out Our Latest Stock Report on HOLX Hologic Profile ( Free Report ) Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Featured Stories Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. ( NASDAQ:HOLX – Free Report ).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter ..
